This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
United Kingdom
Absynth develops vaccines and antibodies to prevent and treat bacterial infections based on its proprietary, non-conventional approach of identifying novel, and conserved bacterial antigens that are essential and antibody accessible. Lead programmes target Staphylococcus aureus, against which, vaccines and antibodies of other companies have failed to show clinical efficacy ? Absynth?s approach has the potential to overcome these previous limitations.
Adaptimmune is focused on the use of T cell therapy to treat cancer and infectious disease. The company aims to utilise the body?s own machinery ? the T cell ? to target and destroy cancerous or infected cells by using engineered, increased affinity T cell receptor (TCRs) as a means of strengthening natural patient T cell responses. Adaptimmune undertakes all of its own research and development using proprietary T cell receptor engineering technology co-developed with its sister company Immunocore Ltd (formerly Avidex/MediGene) and exclusively licensed for T cell therapy. Backed by private investors, Adaptimmune is now in the clinic in the US, in HIV as well as multiple cancer indications with its engineered TCR to the NY-ESO-1/LAGE-1 cancer testis antigen.
AERES Biomedical is engaged in the development of therapeutic antibodies to target all major life threatening and debilitating diseases.
Allergy Therapeutics is a European-based speciality pharmaceutical company focused upon the treatment and prevention of allergy. AT's current portfolio of competitive products includes products containing allergoids, (modified allergens) tyrosine depot and MPL
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids. The company lead product comprises Vascepa, a prescription-only omega-3 fatty acid comprising icosapent ethyl as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Amura is a company dedicated to the development of protease inhibitors. Company's development candidates for cathepsin S (AM-3840), K (AM-3701) and a mixed S/K profile (AM-3876) are ready for GMP synthesis, regulatory safety studies and clinical assessment giving a wealth of opportunities in large market indications such as chronic neuropathic pain, autoimmunity (e.g. rheumatoid arthritis), osteoporosis, osteoarthritis, bone metastasis, and malaria.
Angiogene Pharmaceuticals Ltd., a drug discovery company, engages in developing drug candidates for the treatment of cancer and other angiogenic diseases. It develops compounds to the preclinical stage and at that point licenses to pharmaceutical and drug development companies.
Antoxis is an Aberdeen-based biotechnology company taking a rational approach to the design and synthesis of targeted antioxidants. The company's proprietary technology is based on novel structural modifications to naturally-occurring flavonoids, found in fruit and vegetables, that greatly enhances their bio-activity and cell protective properties, whilst also imparting better pharmaceutical characteristics.
Aquapharm is an innovative discovery company pioneering the development of new breakthrough products founded on the vast, untapped diversity of marine micro-organisms. Aquapharm's core focus is the development of new pharmaceuticals from its marine microbial collection using its SeaRch? technology to address areas of high unmet medical need, in particular Gram negative and Gram positive antibiotics.
Archimedes Pharma is an international specialty pharmaceutical company providing novel and advanced treatments to address unmet needs for people living with serious or life?threatening chronic and debilitating illnesses. Company?s diverse portfolio of specialty products focused on the oncology, pain, and critical care sectors.
Asterion's mission is to design and develop superior, patient-friendly drugs for the treatment of serious chronic and acute disorders. Asterion?s technology harnesses Nature?s use of binding proteins in a simple but revolutionary way.
Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed and out-licensed DACOGEN